Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil

To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerqueira-Silva, Thiago, de Araujo Oliveira, Vinicius, Paixão, Enny S., Júnior, Juracy Bertoldo, Penna, Gerson O., Werneck, Guilherme L., Pearce, Neil, Barreto, Maurício L., Boaventura, Viviane S., Barral-Netto, Manoel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289933/
https://www.ncbi.nlm.nih.gov/pubmed/35851597
http://dx.doi.org/10.1038/s41467-022-31839-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289933/
https://www.ncbi.nlm.nih.gov/pubmed/35851597
http://dx.doi.org/10.1038/s41467-022-31839-7

Ejemplares similares